R-708-5p is a stress-regulated microRNA and a potential biomarker for the differential diagnosis of human mood disorders.

Johnson & Johnson (J&J) is dropping its Phase III major depressive disorder (MDD) programme for aticaprant due to ...

Analysts say the decision is a “big blow” to a once-promising class of brain therapies that include’s J&J’s aticaprant and a ...

J&J is already seeing strong sales growth for its treatment-resistant depression (TRD) and MDD therapy Spravato (esketamine), ...

(Reuters) -Johnson & Johnson will stop late-stage studies of its experimental drug to treat major depressive disorder due to ...